2MD, Prof., Ophthalmology of Department, Faculty of Medicine, Ankara University, Ankara, Türkiye
3MD, Assoc Prof., Ophthalmology of Department, Ankara Bilkent City Hospital, Ankara, Türkiye
4MD, Prof.,Ophthalmology of Department, Ankara Bilkent City Hospital, Ankara, Türkiye DOI : 10.37844/TJ-CEO.2024.19.10 Purpose: To evaluate the clinical outcomes, surgical indications, results of medical, surgical and micropulse transscleral cyclophotocoagulation (MP-TSCPC) treatment in patients with postkeratoplasty glaucoma.
Materials and Methods: Fifty-six eyes of 53 patients with glaucoma who had undergone keratoplasty were included in the study. Demographic and clinical characteristics, medical and surgical (either trabeculectomy or MP-TSCPC) treatment results were evaluated retrospectively.
Results: The mean age of patients was 52.8 ± 19.1 years (9- 84). The most common indication for keratoplasty was bullous keratopathy in 15 eyes (26.8 %). The mean follow-up period was 29.3 ± 36.7 months. Glaucoma control was achieved by medical treatment in 46 (82.1%), MP-TSCPC in 5 (8.9%), trabeculectomy in 3(5.4%), and combined therapy in 2 (3.6%) of eyes. For MP-TSCPC cases the mean pre-treatment IOP was 28.5 mmHg and the mean post-treatment IOP was 14.6 mmHg. With % 40 reduction, the best results were taken in MP-TSCPC group. No patients had hipotony or graft failure.
Conclusions: Glaucoma control can be achieved by medical, surgical and MP-TSCPC treatment in eyes with postkeratoplasty. MPTSCPC is a safe and effective IOP lowering method in these eyes.
Keywords : Glaucoma, keratoplasty, micropulse laser, micropulse transscleral cyclophotocoagulation, postkeratoplasty glaucoma